Inventiva (NASDAQ:IVA) Trading Up 1.3% - Here's Why

Inventiva S.A. (NASDAQ:IVA - Get Free Report) shares shot up 1.3% on Monday . The stock traded as high as $3.24 and last traded at $3.15. 7,314 shares were traded during trading, a decline of 88% from the average session volume of 63,046 shares. The stock had previously closed at $3.11.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the stock. Guggenheim cut their price objective on shares of Inventiva from $12.00 to $9.00 and set a "buy" rating for the company in a research report on Friday, April 4th. HC Wainwright reissued a "buy" rating and issued a $13.00 price target on shares of Inventiva in a report on Friday, March 28th. Finally, TD Cowen assumed coverage on shares of Inventiva in a report on Friday, February 21st. They issued a "buy" rating and a $10.00 price target on the stock. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, Inventiva has a consensus rating of "Moderate Buy" and a consensus price target of $10.40.

Inventiva Price Performance

The company's 50-day moving average is $3.27 and its two-hundred day moving average is $2.79.

Hedge Funds Weigh In On Inventiva

A hedge fund recently bought a new stake in Inventiva stock. Wealth Enhancement Advisory Services LLC bought a new position in Inventiva S.A. (NASDAQ:IVA - Free Report) in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 10,715 shares of the company's stock, valued at approximately $32,000. 19.06% of the stock is currently owned by institutional investors and hedge funds.

About Inventiva

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.